Building cross-border collaborations to increase diversity and accelerate rare disease drug development - meeting report from the inaugural IndoUSrare Annual Conference 2021.

Therapeutic advances in rare disease Pub Date : 2022-10-17 eCollection Date: 2022-01-01 DOI:10.1177/26330040221133124
Harvinder Kour Khera, Nisha Venugopal, Ramya T Karur, Rakesh Mishra, Reena V Kartha, Harsha K Rajasimha
{"title":"Building cross-border collaborations to increase diversity and accelerate rare disease drug development - meeting report from the inaugural IndoUSrare Annual Conference 2021.","authors":"Harvinder Kour Khera,&nbsp;Nisha Venugopal,&nbsp;Ramya T Karur,&nbsp;Rakesh Mishra,&nbsp;Reena V Kartha,&nbsp;Harsha K Rajasimha","doi":"10.1177/26330040221133124","DOIUrl":null,"url":null,"abstract":"<p><p>The inaugural IndoUSrare Annual Conference was held virtually from 29 November to 2 December 2021 and was organized by the Indo US Organization for Rare Diseases (IndoUSrare). The event saw participation from over 250 stakeholders of rare diseases who joined in virtually by audio/video on the Zoom platform from around the world, with a majority of attendees concentrated in the Indian subcontinent and the United States. The conference was held over 4 days from 10:00 a.m. to 12:30 p.m. Eastern Time on each day, which accommodated participation by speakers and attendees from both the eastern and western hemispheres. The agenda over 4 days holistically covered broad topics of interest to different stakeholder groups such as representatives from organizations working toward policy frameworks for rare diseases or orphan drugs (Days 1, 4), biomedical research institutions (Day 2), patient advocacy organizations (Day 3), and patient advocacy and engagement offices within Industry (Day 4). In this meeting report, we summarize the key highlights from each day of this conference, with a perspective on future directions encouraging cross-border multistakeholder collaborations to maximize diversity, equity, and inclusion (DEI) in rare disease diagnosis, research, clinical trials, and treatment access. Each day included a keynote lecture on the theme of the day followed by a series of individual speaker presentations and/or a panel discussion. The goal was to understand current barriers and bottlenecks in the rare disease ecosystem. The discussions also helped highlight gaps and identify potential solutions that can be achieved through building multistakeholder collaborations across international borders, which we believe IndoUSrare is uniquely positioned to do with organizational programs such as rare patient foundation alliance, technology-enabled patient concierge, research corps, and corporate alliance program. The inaugural conference of the then 2+-year-old IndoUSrare organization laid the foundation for ongoing engagement of stakeholders between the two countries - the United States and India. The long-term goal is to scale the conference more broadly and serve as a model for other low- and middle-income countries (LMICs).</p><p><strong>Plain language summary: </strong>IndoUSrare held its inaugural Annual Conference from 29 November to 2 December 2021. It was focused on the theme of cross-border collaborations for rare disease drug development, with each day dedicated to a specific patient-focused discussion topic, ranging from patient-led advocacy (Advocacy Day), research (Research Day), rare disease community support and engagement (Patients Alliance Day), to industry collaborations (Industry Day). The 4-day conference was held in virtual mode and attracted over 250 attendees from across the globe. This meeting report provides the key highlights of the event and summarizes learnings and future directions encouraging cross-border collaborations to increase diversity, equity, and inclusion (DEI) in rare disease research and clinical trials.</p>","PeriodicalId":75218,"journal":{"name":"Therapeutic advances in rare disease","volume":"3 ","pages":"26330040221133124"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/81/10.1177_26330040221133124.PMC10032468.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic advances in rare disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26330040221133124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The inaugural IndoUSrare Annual Conference was held virtually from 29 November to 2 December 2021 and was organized by the Indo US Organization for Rare Diseases (IndoUSrare). The event saw participation from over 250 stakeholders of rare diseases who joined in virtually by audio/video on the Zoom platform from around the world, with a majority of attendees concentrated in the Indian subcontinent and the United States. The conference was held over 4 days from 10:00 a.m. to 12:30 p.m. Eastern Time on each day, which accommodated participation by speakers and attendees from both the eastern and western hemispheres. The agenda over 4 days holistically covered broad topics of interest to different stakeholder groups such as representatives from organizations working toward policy frameworks for rare diseases or orphan drugs (Days 1, 4), biomedical research institutions (Day 2), patient advocacy organizations (Day 3), and patient advocacy and engagement offices within Industry (Day 4). In this meeting report, we summarize the key highlights from each day of this conference, with a perspective on future directions encouraging cross-border multistakeholder collaborations to maximize diversity, equity, and inclusion (DEI) in rare disease diagnosis, research, clinical trials, and treatment access. Each day included a keynote lecture on the theme of the day followed by a series of individual speaker presentations and/or a panel discussion. The goal was to understand current barriers and bottlenecks in the rare disease ecosystem. The discussions also helped highlight gaps and identify potential solutions that can be achieved through building multistakeholder collaborations across international borders, which we believe IndoUSrare is uniquely positioned to do with organizational programs such as rare patient foundation alliance, technology-enabled patient concierge, research corps, and corporate alliance program. The inaugural conference of the then 2+-year-old IndoUSrare organization laid the foundation for ongoing engagement of stakeholders between the two countries - the United States and India. The long-term goal is to scale the conference more broadly and serve as a model for other low- and middle-income countries (LMICs).

Plain language summary: IndoUSrare held its inaugural Annual Conference from 29 November to 2 December 2021. It was focused on the theme of cross-border collaborations for rare disease drug development, with each day dedicated to a specific patient-focused discussion topic, ranging from patient-led advocacy (Advocacy Day), research (Research Day), rare disease community support and engagement (Patients Alliance Day), to industry collaborations (Industry Day). The 4-day conference was held in virtual mode and attracted over 250 attendees from across the globe. This meeting report provides the key highlights of the event and summarizes learnings and future directions encouraging cross-border collaborations to increase diversity, equity, and inclusion (DEI) in rare disease research and clinical trials.

Abstract Image

Abstract Image

Abstract Image

建立跨境合作以增加多样性并加快罕见病药物开发——首届2021年印度罕见病年会的会议报告。
首届印度罕见病年会于2021年11月29日至12月2日举行,由印度罕见病组织组织。来自世界各地的250多名罕见病利益相关者通过Zoom平台上的音频/视频参与了此次活动,其中大多数与会者集中在印度次大陆和美国。会议于美国东部时间每天上午10:00至下午12:30举行,为期4天,有来自东半球和西半球的发言者和与会者参加。为期4天的议程全面涵盖了不同利益相关者群体感兴趣的广泛主题,如致力于制定罕见病或孤儿药政策框架的组织代表(第1天、第4天)、生物医学研究机构代表(第2天)、患者倡导组织代表(第一天)以及行业内的患者倡导和参与办公室代表(第4天。在这份会议报告中,我们总结了本次会议每天的主要亮点,并展望了鼓励跨境多利益相关者合作的未来方向,以最大限度地提高罕见病诊断、研究、临床试验和治疗途径的多样性、公平性和包容性。每天都有一场主题演讲,随后是一系列个人演讲和/或小组讨论。目标是了解罕见病生态系统中目前的障碍和瓶颈。这些讨论还有助于突出差距,并确定可以通过跨国际边界建立多方利益相关者合作来实现的潜在解决方案,我们认为IndoUSrare在罕见病患基金会联盟、技术支持的患者礼宾、研究团队和企业联盟计划等组织项目方面具有独特的地位。成立两年多的IndoUSrare组织的首次会议为美国和印度两国利益相关者的持续参与奠定了基础。长期目标是更广泛地扩大会议规模,并为其他中低收入国家(LMIC)树立榜样。简明的语言摘要:IndoUSrare于2021年11月29日至12月2日举行了首届年会。它专注于罕见病药物开发的跨境合作主题,每天专门讨论一个以患者为中心的特定讨论主题,从患者主导的倡导(倡导日)、研究(研究日)、罕见病社区支持和参与(患者联盟日)到行业合作(行业日)。为期4天的会议以虚拟模式举行,吸引了来自全球各地的250多名与会者。本会议报告提供了此次活动的主要亮点,并总结了鼓励跨境合作以提高罕见病研究和临床试验的多样性、公平性和包容性(DEI)的经验教训和未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信